## <u>AMENDMENTS</u>

Claims 1 – 37 Cancelled.

- 38. (Currently Amended) A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination: a flow measuring device to test for cerebral vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to increase, decrease or substitute another medicine to minimize occurrence and severity of said vasospasm.
- 39. (Previously Added) A system according to Claim 38 wherein the flow measuring device comprises transcranial Doppler measuring means.
- 40. (Previously Added) A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, isradipine, hydrazine, nifedipine, and/or other medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.
- 41. (Previously Added) A system according to Claim 38 wherein the flow measuring device comprises transcranial doppler measuring means and the dosage

device comprises transdermal, inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

- 42. (Previously Added) A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.
- 43. (Previously Added) A system according to Claim 46 wherein the delivery system is adapted for transdermal delivery.
- 44. (Previously Added) A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.